US EditionPublished • loading... • Updated
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
ADC Therapeutics issued 47,000 stock options to incentivize two new hires as part of its Inducement Plan approved by the Compensation Committee.
- Lausanne-based ADC Therapeutics SA announced yesterday it granted 47,000 options to two new employees as material inducements under Rule 303A.08.
- The Compensation Committee of ADC Therapeutics' Board of Directors approved the awards under the Inducement Plan to motivate recipients and support ADC Therapeutics SA's success.
- Vesting begins with 25% on the first anniversary, then 1/48th monthly, and fully vests after four years subject to continued employment.
- ADC Therapeutics is a commercial-stage ADC specialist with an approved product, marketing ZYNLONTA with FDA accelerated and European Commission conditional approvals and advancing an exatecan-based PSMA-targeting ADC.
- The release notes it contains forward-looking statements and refers investors to its Annual Report on Form 10-K 'Risk Factors' section, listing Investors and Media contact Nicole Riley and adctherapeutics.com.
Insights by Ground AI
46 Articles
46 Articles
Bennington Banner+45 Reposted by 45 other sources
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Dec. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate…
Coverage Details
Total News Sources46
Leaning Left4Leaning Right7Center13Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 17%
C 54%
R 29%
Factuality
To view factuality data please Upgrade to Premium
